The evolving blood donor deferral policy for men who have sex with men: impact on the risk of HIV transmission by transfusion in France.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
10
10
2019
revised:
10
12
2019
accepted:
19
12
2019
pubmed:
7
2
2020
medline:
8
9
2020
entrez:
7
2
2020
Statut:
ppublish
Résumé
Blood donation deferral for men who have sex with men (MSM) in France was reduced from permanent to 12 months in July 2016. To inform a further reduction of the deferral period, an HIV risk assessment was conducted with two scenarios: S1, 4-month deferral; S2, 4-month deferral only in the case of more than one sexual partner (i.e., similar to other blood donors). Baseline HIV residual risk (RR) was calculated from July 2016 to December 2017, using the Incidence Rate-Window Period method. The impact of both scenarios on RR was assessed using data from surveys on MSM and blood donors, to estimate 1) the number of additional MSM expected to donate in each scenario and 2) HIV incidence among these donors. Baseline HIV RR was estimated at 1 in 6,380,000 donations. For S1, an additional 733 MSM donors, and an additional 0.09 HIV-positive donations were estimated, yielding an unchanged RR of 1 in 6,300,000. For S2, these numbers were estimated at 3102 and 3.92, respectively, yielding an RR of 1 in 4,300,000. Sensitivity analyses showed that, under worst-case assumptions, the RR would equal 1 in 6,225,000 donations for S1 and 1 in 3,000,000 for S2. For both scenarios, the HIV RR remains very low. For S1, the risk is identical to the baseline RR. For S2, it is 1.5 times higher, and sensitivity analysis shows that this estimate is less robust than for S1. The French Minister of Health announced that S1 will be implemented in April 2020.
Sections du résumé
BACKGROUND
Blood donation deferral for men who have sex with men (MSM) in France was reduced from permanent to 12 months in July 2016. To inform a further reduction of the deferral period, an HIV risk assessment was conducted with two scenarios: S1, 4-month deferral; S2, 4-month deferral only in the case of more than one sexual partner (i.e., similar to other blood donors).
METHODS
Baseline HIV residual risk (RR) was calculated from July 2016 to December 2017, using the Incidence Rate-Window Period method. The impact of both scenarios on RR was assessed using data from surveys on MSM and blood donors, to estimate 1) the number of additional MSM expected to donate in each scenario and 2) HIV incidence among these donors.
RESULTS
Baseline HIV RR was estimated at 1 in 6,380,000 donations. For S1, an additional 733 MSM donors, and an additional 0.09 HIV-positive donations were estimated, yielding an unchanged RR of 1 in 6,300,000. For S2, these numbers were estimated at 3102 and 3.92, respectively, yielding an RR of 1 in 4,300,000. Sensitivity analyses showed that, under worst-case assumptions, the RR would equal 1 in 6,225,000 donations for S1 and 1 in 3,000,000 for S2.
CONCLUSION
For both scenarios, the HIV RR remains very low. For S1, the risk is identical to the baseline RR. For S2, it is 1.5 times higher, and sensitivity analysis shows that this estimate is less robust than for S1. The French Minister of Health announced that S1 will be implemented in April 2020.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
525-534Informations de copyright
© 2020 AABB.
Références
Goldman M, W-Y Shih A, OʼBrien SF, et al. Donor deferral policies for men who have sex with men: past, present and future. Vox Sang 2018;113:95-103.
Tiberghien P, Pillonel J, Toujas F, et al. Changes in Franceʼs deferral of blood donation by men who have sex with men. N Engl J Med 2017;376:1485-6.
Pillonel J, Sauvage C, Charpentier F, et al. Bilan sur le respect des critères de sélection des donneurs de sang deux ans après leur modification. Saint-Maurice: Santé publique France; 2018.
Sauvage C, Spinardi R, Pelat C, et al. Steering CommitteeNoncompliance with blood donor selection criteria - Complidon, France. Transfusion 2020;60(1):73-83.
Schreiber GB, Busch M, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-90.
Barin F, Meyer L, Lancar R, et al. Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J Clin Microbiol 2005;43:4441-7.
Pillonel J, Barin F, Laperche S, et al. Human immunodeficiency virus type 1 incidence among blood donors in France, 1992 through 2006: use of an immunoassay to identify recent infections. Transfusion 2008;48:1567-75.
Busch M, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005;45:254-64.
Bajos N, Rahib D, Lydié N. Genre et sexualité. Dʼune décennie à lʼautre. Baromètre santé 2016. Saint-Maurice: Santé publique France; 2018.
Velter A, Duchesne L, Lydié N. Pourquoi lʼépidémie du VIH se poursuit-elle parmi les hommes ayant des relations sexuelles avec des hommes (HSH) en France ? AFRAVIH - 9ème Conférence Internationale Francophone VIH/hépatites; 4-7 avril 2018, Bordeaux, France. 2018.
Duchesne L, Velter A, Lydié N. Comportements préventifs au dernier rapport sexuel chez les HSH à lʼère de la prévention diversifiée - Enquête ERAS AFRAVIH - 9ème Conférence Internationale Francophone VIH/hépatites; 4-7 avril 2018, Bordeaux, France.
Sommen C, Saboni L, Sauvage C, et al. Time location sampling in men who have sex with men in the HIV context: the importance of taking into account sampling weights and frequency of venue attendance. Epidemiol Infect 2018;146:913-9.
Sommen C, Cazein F, Le Strat Y, Pillonel J, Lot F, Le Vu S, Barin F. Updated estimates of hiv incidence for France, 2003-2014. 9th IAS Conference on HIV Science; 2017 July 23-26, Paris, France.
Presanis AM, Gill ON, Chadborn TR, et al. Insights into the rise in HIV infections, 2001 to 2008: a Bayesian synthesis of prevalence evidence. AIDS 2010;24:2849-58.
Plummer M. rjags: Bayesian graphical models using MCMC. R package version 4-8; 2018.
R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2018.
Pillonel J, Heraud-Bousquet V, Pelletier B, et al. Deferral from donating blood of men who have sex with men: impact on the risk of HIV transmission by transfusion in France. Vox Sang 2012;102:13-21.
Germain M. The risk of allowing blood donation from men having sex with men after a temporary deferral: predictions versus reality. Transfusion 2016;56:1603-7.
Bajos N, Beltzer N, Prudhomme A. Les sexualités homo-bisexuelles: dʼune acceptation de principe aux vulnérabilités sociales et préventives In: Enquête sur la sexualité en France: La Découverte; 2008: p. 243-71.
Purcell DW, Johnson CH, Lansky A, et al. Estimating the population size of men who have sex with men in the United States to obtain HIV and syphilis rates. Open AIDS J 2012;6:98-107.
Marcus U, Schmidt AJ, Kollan C, et al. The denominator problem: estimating MSM-specific incidence of sexually transmitted infections and prevalence of HIV using population sizes of MSM derived from Internet surveys. BMC Public Health 2009;9:181.
Kellogg TA, Hecht J, Bernstein K, et al. Comparison of HIV behavioral indicators among men who have sex with men across two survey methodologies, San Francisco, 2004 and 2008. Sex Transm Dis 2013;40:689-94.
Donor selection criteria report. SaBTO; 2017.
Héma Quebec. Man who had sex with a man - change to the eligibility criterion for giving blood starting June 3, 2019.
OʼBrien SF, Grégoire Y, Pillonel J, et al. HIV residual risk in Canada under a three-month deferral for men who have sex with men. Vox Sang 2019 Nov 27. doi: 10.1111/vox.12867.
OʼBrien SF, Osmond L, Fan W, et al. Compliance with time based deferrals for men who have sex with men. Transfusion 2019;59:916-20.
Vermeulen M, Lelie N, Coleman C, et al. Assessment of HIV transfusion transmission risk in South Africa: a 10-year analysis following implementation of individual donation nucleic acid amplification technology testing and donor demographics eligibility changes. Transfusion 2018;59:267-76.
Heiden M, Ritter S, Hamouda O, et al. Estimating the residual risk for HIV, HCV and HBV in different types of platelet concentrates in Germany. Vox Sang 2015;108:123-30.
OʼBrien SF, Yi Q-L, Fan W, et al. Current incidence and residual risk of HIV, HBV and HCV at Canadian Blood Services. Vox Sang 2012;103:83-6.
Zou S, Stramer SL, Dodd RY. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agent in US allogeneic donations. Transfus Med Rev 2012;26:119-28.
Davison K, Brant L, Presanis A, et al. A re-evaluation of the risk of transfusion-transmitted HIV prevented by the exclusion of men who have sex with men from blood donation in England and Wales, 2005-2007. Vox Sang 2011;101:291-302.
Germain M, Robillard P, Delage G, et al. Allowing blood donation from men who had sex with men more than 5 years ago: a model to evaluate the impact on transfusion safety in C anada. Vox Sang 2014;106:372-5.
Davison KL, Gregoire Y, Germain M, et al. Changing the deferral for men who have sex with men - an improved model to estimate HIV risk. Vox Sang 2019 Oct;114(7):666-74. doi: 10.1111/vox.12826.
Busch M, Watanabe K, Smith J, et al. False-negative testing errors in routine viral marker screening of blood donors. Transfusion 2000;40:585-9.
Billioti de Gage S, Le Tri T, Dray-Spira R. Suivi de lʼutilisation de Truvada® ou génériques pour une prophylaxie pré-exposition (PrEP) au VIH à partir des données du Système National des Données de Santé (SNDS). Epi-Phare; 2019.
Seed C, Yang H, Lee J. Blood safety implications of donors using HIV pre-exposure prophylaxis. Vox Sang 2017;112:473-6.